Monday, December 21, 2020

Interferon Beta-1a May Help COVID-19 Patients Recover Faster

Main article image
 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

Results of a clinical trial published in The Lancet Respiratory Medicine showed the inhaled immune response protein interferon beta-1a reduced the chances of hospitalized COVID-19 patients becoming severely ill or dying of their infection. read more ]

Moderna's COVID-19 Vaccine Is 94.1 Percent Effective with No Severe Disease

Final results from Moderna's 30,000-person efficacy trial for its COVID-19 vaccine showed only 11 people who received two doses of the vaccine developed COVID-19 symptoms after being infected with the pandemic coronavirus, versus 185 symptomatic cases in a placebo group, an efficacy of 94.1 percent. In addition, it had 100 percent efficacy against severe disease, with zero such COVID-19 cases among those vaccinated versus 30 in the placebo group. read more ]

ACIP Issues Interim Guidance for Allocation of COVID-19 Vaccine

With demand expected to exceed supply during the first months of the national COVID-19 vaccination program, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has recommended, as interim guidance, that both healthcare personnel and residents of long-term care facilities be offered the COVID-19 vaccine in the initial phase. read more ]

Industry News

 
Industry News Image
 

From Regeneron

The U.S. Department of Health and Human Services plans to allocate initial doses of Regeneron's investigational monoclonal antibody therapeutic, casirivimab and imdevimab, which received emergency use authorization from the U.S. Food and Drug Administration on Nov. 21, 2020, for treatment of nonhospitalized patients with mild or moderate confirmed cases of COVID-19 at high risk of hospitalization.  [ read more ]

From Eli Lilly

The U.S. Food and Drug Administration has given emergency use clearance to Eli Lilly's experimental antibody drug to treat people 12 years and older with mild or moderate COVID-19 not requiring hospitalization. read more ]

IVIG & Albumin Supply Index

IVIG and Albumin Days On Hand
     
 
 
 
     

What's New at FFF

FENTANYL CITRATE (HOSPIRA INC.)

FENTANYL CITRATE injection is indicated for 1) analgesic action of short duration during the anesthetic periods, premedication, induction and maintenance, and in the immediate postoperative period (recovery room) as the need arises; 2) use as an opioid analgesic supplement in regional anesthesia; 3) administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the maintenance of general and regional anesthesia; and 4) use as an anesthetic agent with oxygen in selected high-risk patients such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures. It is supplied in single-dose glass containers as clamcells of (10) 2 mL and 5 mL single-dose ampules; trays containing (25) 2 mL, 5 mL, 10 mL, 20 mL and 50 mL single-dose fliptop vials; and cartons containing (5) 10 mL and 20 mL single-dose ampules.

For more information about FENTANYL CITRATE, log in to biosupply.fffenterprises.com

XERAVA (ERAVACYCLINE) (TETRAPHASE PHARAMACEUTICALS)

XERAVA (ERAVACYCLINE) for injection is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. The yellow to orange sterile, preservative-free powder for reconstitution is supplied in single-dose 10 mL clear glass vials in 50 mg and 100 mg doses with a rubber stopper and an aluminum overseal.

For more information about XERAVA (ERAVACYCLINE), log in to biosupply.fffenterprises.com

PROTONIX I.V. (PFIZER)*

PROTONIX I.V. (pantoprazole sodium) for injection is indicated in adults for 1) short-term treatment (seven to 10 days) of gastroesophogeal reflex disease associated with a history of erosive esophagitis, and 2) pathological hypersecretion conditions, including Zollinger-Ellison syndrome. It is supplied as a single-dose vial as a white to off-white freeze-dried powder for reconstitution containing 40 mg of pantoprazole in packages of 10 and 25 vials.

For more information about PROTONOX I.V., log in to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

SULFAMETHOXAZOLE AND TRIMETHOPRIM (SOMERSET THERAPEUTICS)

SULFAMETHOXAZOLE and TRIMETHOPRIM injection is a combination of sulfamethoxazole, a sulfonamide antimicrobial, and trimethoprim, a dihydrofolate reductase inhibitor antibacterial, indicated in adults and pediatric patients 2 months of age and older for treatment of infections caused by designated, susceptible bacteria. It is supplied in 5 mL single-dose and 10 mL and 30 mL multiple-dose vials, with each 5 mL dose containing 80 mg trimethoprim (16 mg/mL) and 400 mg sulfamethoxazole (80 mg/mL) for infusion with 5% dextrose in water.

For more information about SULFAMETHOXAZOLE and TRIMETHOPRIM, log in to biosupply.fffenterprises.com

DEXMEDETOMIDINE HYDROCHLORIDE (BAXTER)

DEXMEDETOMIDINE HYDROCHLORIDE in 0.9% sodium chloride injection is a relatively selective alpha2-adrenergic agonist indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, and sedation of nonintubated patients prior to and/or during surgical and other procedures. It is available as 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL) in 50 mL and 100 mL GALAXY containers, respectively.

For more information about DEXMEDETOMIDINE HYDROCHLORIDE, log in to biosupply.fffenterprises.com

IXINITY (APTEVO BIOTHERAPEUTICS)

IXINITY (coagulation factor IX [recombinant]) is a human blood coagulation factor indicated for adults and children 12 years and older with hemophilia B for control and prevention of bleeding episodes and perioperative management. It is supplied as a lyophilized powder in single-use glass vials containing the labeled amount of factor IX activity, expressed in international units (IU). Kits include one single-use vial (containing nominally 250, 500, 1000, 1500, 2000 and 3000 IU per vial), a 10 mL syringe prefilled with 5 mL of sterile water for injection with plunger rod attached, and a vial adapter with filter.

For more information about IXINITY, log in to biosupply.fffenterprises.com

STERILE WATER (WEST-WARD PHARMACEUTICALS)

STERILE WATER for injection is a sterile nonpyrogenic preparation of water that contains no bacteriostat, antimicrobial agent or added buffer designed solely for parenteral use only after addition of drugs that require dilution or must be dissolved in an aqueous vehicle prior to injection. It is supplied only in single-dose containers to dilute or dissolve drugs for injection.

For more information about STERILE WATER, log in to biosupply.fffenterprises.com

AMIODARONE HYDROCHLORIDE (WEST-WARD PHARMACEUTICALS)

AMIODARONE HYDROCHLORIDE injection is an antiarrhythmic agent indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. The 50 mg/mL injection dosage is supplied in 3 mL single-dose vials in cartons of 10 and 25.

For more information about AMIODARONE HYDROCHLORIDE, log in to biosupply.fffenterprises.com

HIZENTRA PRE-FILLED SYRINGES (CSL BEHRING)

HIZENTRA (immune globulin subcutaneous [human] 20% liquid) PRE-FILLED SYRINGES for primary immunodeficiency patients are ready to use, eliminating the need to transfer the drug from the vial to a syringe. The syringes come in 5 mL and 10 mL (fully assembled) and 20 mL (requiring the plunger rod to be screwed onto the syringe stopper prior to use).

For more information about HIZENTRA PRE-FILLED SYRINGES, log in to biosupply.fffenterprises.com

ALBUMINEX 5% (BIO PRODUCTS LABORATORY)

ALBUMINEX 5% is a 5% albumin solution indicated for adults and children to treat hypovolemia; ascites; hypoalbuminemia, including from burns; acute nephrosis; acute respiratory distress syndrome; and cardiopulmonary bypass. It is supplied in 5 g/dL clear type II glass vials.

For more information about ALBUMINEX 5%, log in to biosupply.fffenterprises.com

ALBUMINEX 25% (BIO PRODUCTS LABORATORY)

ALBUMINEX 25% is a 25% albumin solution indicated for adults and children to treat hypovolemia; ascites; hypoalbuminemia, including from burns; acute nephrosis; acute respiratory distress syndrome; and cardiopulmonary bypass. It is supplied in 25 g/dL clear type II glass vials.

For more information about ALBUMINEX 25%, log in to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Oct. 1, 2020, through Dec. 31, 2020.

 
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
FLEBOGAMMA J1572 $80.77 $79.47
GAMMAGARD SD J1566 $136.61 $134.42
GAMMAPLEX J1557 $107.32 $105.60
OCTAGAM J1568 $82.46 $81.14
PANZYGA 90283 / J1599 ** **
PRIVIGEN J1459 $83.01 $81.67
SCIG
CUTAQUIG 90284 / J3590 ** **
CUVITRU J1555 $140.22 $137.97
HIZENTRA J1559 $108.55 $106.81
HYQVIA J1575 $144.86 $142.54
XEMBIFY J1558 $142.23 $139.95
IVIG / SCIG
GAMMAGARD LIQUID J1569 $86.40 $85.02
GAMMAKED J1561 $84.37 $83.02
GAMUNEX-C J1561 $84.37 $83.02

* Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.
** ASP-based Medicare payment rate not yet available; payment rate assigned by your Medicare Administrative Contractor.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – © FFF Enterprises, Inc.